Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hongcheng Zhu

Showing results (81-90 of 88) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 88 results.
Radiation Oncology (London, England)|July 29, 2022
Dose escalation based on <sup>18</sup>F-FDG PET/CT response in definitive chemoradiotherapy of locally advanced esophageal squamous cell carcinoma: a phase III, open-label, randomized, controlled trial (ESO-Shanghai 12)Hongcheng Zhu, Qiufang Liu, Hao Xu, et al.
The Lancet. Global Health|October 14, 2024
Global radiotherapy demands and corresponding radiotherapy-professional workforce requirements in 2022 and predicted to 2050: a population-based studyHongcheng Zhu, Melvin Lee Kiang Chua, Imjai Chitapanarux, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 16, 2025
Radiotherapy for Unresectable Locally Advanced NSCLC: A Practical Multidisciplinary Approach to Challenging Scenarios From the International Association for the Study of Lung Cancer Advanced Radiation Technology SubcommitteeHongcheng Zhu, Said Al Saifi, Houda Bahig, et al.
Future Oncology (London, England)|March 4, 2026
Precision palliative care in advanced/recurrent esophageal cancer patients treated with anti-PD-1/PD-L1 immunotherapy (ESO-Shanghai 25): a randomized, phase III TrialShengnan Hao, Xiaomin Wang, Huiping Ding, et al.
Future Oncology (London, England)|July 30, 2025
ESO-Shanghai 20: phase III clinical trial of anti-PD-1 therapy with local intervention for oligometastatic ESCCGuangmin Mao, Zhuocheng Xin, Qingsong Fan, et al.
International Journal of Radiation Oncology, Biology, Physics|March 7, 2021
Involved-Field Irradiation in Definitive Chemoradiotherapy for Locoregional Esophageal Squamous Cell Carcinoma: Results From the ESO-Shanghai 1 TrialHongcheng Zhu, Eleonor Rivin Del Campo, Jinjun Ye, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2025
Radiation Dose-Volume Effects on Negative Tumor-Draining Lymph Nodes Affected T-cell Activation and Prognosis in Esophageal Cancer with ChemoradiotherapyIhsuan Tseng, Yun Chen, Dashan Ai, et al.
The Lancet. Oncology|October 3, 2024
Radiotherapy and theranostics: a Lancet Oncology CommissionMay Abdel-Wahab, Francesco Giammarile, Mauro Carrara, et al.
Pageof 9

Showing results (81-90 of 88) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 88 results.
Radiation Oncology (London, England)|July 29, 2022
Dose escalation based on <sup>18</sup>F-FDG PET/CT response in definitive chemoradiotherapy of locally advanced esophageal squamous cell carcinoma: a phase III, open-label, randomized, controlled trial (ESO-Shanghai 12)Hongcheng Zhu, Qiufang Liu, Hao Xu, et al.
The Lancet. Global Health|October 14, 2024
Global radiotherapy demands and corresponding radiotherapy-professional workforce requirements in 2022 and predicted to 2050: a population-based studyHongcheng Zhu, Melvin Lee Kiang Chua, Imjai Chitapanarux, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 16, 2025
Radiotherapy for Unresectable Locally Advanced NSCLC: A Practical Multidisciplinary Approach to Challenging Scenarios From the International Association for the Study of Lung Cancer Advanced Radiation Technology SubcommitteeHongcheng Zhu, Said Al Saifi, Houda Bahig, et al.
Future Oncology (London, England)|March 4, 2026
Precision palliative care in advanced/recurrent esophageal cancer patients treated with anti-PD-1/PD-L1 immunotherapy (ESO-Shanghai 25): a randomized, phase III TrialShengnan Hao, Xiaomin Wang, Huiping Ding, et al.
Future Oncology (London, England)|July 30, 2025
ESO-Shanghai 20: phase III clinical trial of anti-PD-1 therapy with local intervention for oligometastatic ESCCGuangmin Mao, Zhuocheng Xin, Qingsong Fan, et al.
International Journal of Radiation Oncology, Biology, Physics|March 7, 2021
Involved-Field Irradiation in Definitive Chemoradiotherapy for Locoregional Esophageal Squamous Cell Carcinoma: Results From the ESO-Shanghai 1 TrialHongcheng Zhu, Eleonor Rivin Del Campo, Jinjun Ye, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2025
Radiation Dose-Volume Effects on Negative Tumor-Draining Lymph Nodes Affected T-cell Activation and Prognosis in Esophageal Cancer with ChemoradiotherapyIhsuan Tseng, Yun Chen, Dashan Ai, et al.
The Lancet. Oncology|October 3, 2024
Radiotherapy and theranostics: a Lancet Oncology CommissionMay Abdel-Wahab, Francesco Giammarile, Mauro Carrara, et al.
Pageof 9